Low Disease Activity State/Remission Predicts a Better Health-Related Quality of Life in Systemic Lupus Erythematosus Patients.
To determine if low disease activity state (LDAS)/Remission predicts a better health-related quality of life (HRQoL). Systemic lupus erythematosus (SLE) patients from a single center with at least two visits were included. Visits were performed every six months. HRQoL was measured with the LupusQoL. Remission: a SLEDAI-2K=0, prednisone daily dose≤5mg/d and immunosuppressive drugs on maintenance dose. LDAS: a SLEDAI-2K≤4, prednisone daily dose≤7.5mg/d and immunosuppressive drugs on maintenance dose; for these analyses, remission and LDAS were combined. Generalized estimating equations were performed, using as outcome each one of the eight components of the LupusQoL in the subsequent visit, and the activity state in the previous visit; multivariable models were adjusted for possible confounders. Two hundred and forty-three patients were included. During the follow-up, 590 (61.6%) visits were categorized as LDAS/remission. LDAS/Remission predicted a better HRQoL in the components of physical health [B=4.17 (95%CI:1.20; 7.14); p=0.006], pain [B=6.47 (95%CI:3.18; 9.76); p<0.001], planning [B=4.97 (95%CI:1.43; 8.52); p=0.006], burden to others [B=4.12 (95%CI:0.24; 8.01); p=0.037], emotional health [B=4.50 (95%CI:1.56; 7.44); p=0.003] and fatigue [B=3.25 (95%CI:0.04; 6.47); p=0.048]. Being on LDAS/Remission predicts a better HRQoL, especially in the components of physical health, pain, planning, burden to others, emotional health and fatigue. This article is protected by copyright. All rights reserved.